Media stories about Aileron Therapeutics (NASDAQ:ALRN) have been trending somewhat positive recently, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aileron Therapeutics earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.8643345212413 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

ALRN has been the topic of a number of recent research reports. Canaccord Genuity reaffirmed a “buy” rating and set a $19.00 price target on shares of Aileron Therapeutics in a research report on Friday, August 11th. Bank of America Corporation began coverage on shares of Aileron Therapeutics in a research report on Monday, July 24th. They set a “buy” rating and a $19.00 target price on the stock. Jefferies Group LLC began coverage on shares of Aileron Therapeutics in a research report on Monday, July 24th. They set a “buy” rating and a $20.00 target price on the stock. Finally, William Blair began coverage on shares of Aileron Therapeutics in a research report on Monday, July 24th. They set an “outperform” rating on the stock.

In related news, insider Lilly Ventures Fund I. Llc purchased 250,000 shares of the stock in a transaction on Wednesday, July 5th. The shares were bought at an average price of $15.00 per share, for a total transaction of $3,750,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Reinhard J. Ambros purchased 266,667 shares of the stock in a transaction on Wednesday, July 5th. The shares were bought at an average price of $15.00 per share, for a total transaction of $4,000,005.00. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 696,667 shares of company stock worth $10,450,005.

TRADEMARK VIOLATION NOTICE: This article was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://theolympiareport.com/2017/09/25/aileron-therapeutics-alrn-receives-daily-news-sentiment-score-of-0-18.html.

About Aileron Therapeutics

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Insider Buying and Selling by Quarter for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.